請參閱英文版

45 people showed up at the last seminar of the Precision Medicine Series. This episode centered on the status quo and challenges faced by the industry and the regulator from the regulatory and legal perspective, worldwide and in Hong Kong, as the trend of precision medicine arrives.

After Mr. Lawrence Wong (Co-Sponsor of the HKAPI R&D Ecosystem Taskforce) gave a brief recap of the previous two seminars and introduced the objective of the third one, Ms. Sabrina Chan (Senior Executive Director of HKAPI), the Moderator, introduced the speakers. Mr. Clement Ngai (Partner of Baker & McKenzie Shanghai) and Mr. Paolo Sbutonni (Partner of Baker & McKenzie Hong Kong) then took over to speak on the regulatory and data privacy concerns on precision medicine from the EU and US perspectives, followed by Mr. Lot Chan (Chief Pharmacist, Drug Office, Department of Health) on the regulatory regime for precision medicine, and at last, Ms. Kim Lee (Chief Scientific Officer, Novartis Pharmaceuticals (HK) Ltd) on what a conducive regulatory and legal environment for precision medicine in Hong Kong should be from the industry perspective.

Questions from the floor raised during the panel discussion session included what Hong Kong’s precision medicine policies are and the possible solutions, as well as how Hong Kong could leverage the Greater Bay Area in the development of precision medicine.

Presentation materials is now available at the member’s area.